Evaxion A/S (EVAX) SEC filings

EVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 5, 2026Score 2/30

$2.74−0.03 (-1.08%)

Close on Nov 13, 2026Market cap $22.85MP/E –Yield –

SEC filings

40 of Evaxion A/S's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Current report	6-K	Nov 12, 2026	Nov 12, 2026	SEC EDGAR
Current report	6-K	Nov 9, 2026	Nov 9, 2026	SEC EDGAR
Current report	6-K	Nov 6, 2026	Nov 6, 2026	SEC EDGAR
Current report	6-K	Nov 4, 2026	Nov 4, 2026	SEC EDGAR
Current report	6-K	Nov 4, 2026	Nov 4, 2026	SEC EDGAR
Current report	6-K	Nov 3, 2026	Nov 3, 2026	SEC EDGAR
Current report	6-K	Oct 30, 2026	Oct 30, 2026	SEC EDGAR
Current report	6-K	Oct 23, 2026	Oct 23, 2026	SEC EDGAR
Current report	6-K	Oct 19, 2026	Oct 19, 2026	SEC EDGAR
Current report	6-K	Oct 2, 2026	Oct 2, 2026	SEC EDGAR
Current report	6-K	Sep 14, 2026	Sep 14, 2026	SEC EDGAR
Current report	6-K	Sep 4, 2026	Sep 4, 2026	SEC EDGAR
Current report	6-K	Aug 20, 2026	Aug 20, 2026	SEC EDGAR
Current report	6-K	Jun 30, 2026	Aug 20, 2026	SEC EDGAR
Current report	6-K	Aug 17, 2026	Aug 17, 2026	SEC EDGAR
Current report	6-K	Aug 14, 2026	Aug 14, 2026	SEC EDGAR
Current report	6-K	Jul 17, 2026	Jul 17, 2026	SEC EDGAR
Current report	6-K	Jul 12, 2026	Jul 13, 2026	SEC EDGAR
Current report	6-K	Jul 1, 2026	Jul 1, 2026	SEC EDGAR
Current report	6-K	Jun 12, 2026	Jun 12, 2026	SEC EDGAR
Current report	6-K	Jun 11, 2026	Jun 11, 2026	SEC EDGAR
Current report	6-K	May 12, 2026	May 12, 2026	SEC EDGAR
Current report	6-K	May 7, 2026	May 7, 2026	SEC EDGAR
Current report	6-K	May 4, 2026	May 4, 2026	SEC EDGAR
Current report	6-K	Apr 27, 2026	Apr 27, 2026	SEC EDGAR
Current report	6-K	Apr 21, 2026	Apr 22, 2026	SEC EDGAR
Current report	6-K	Apr 17, 2026	Apr 17, 2026	SEC EDGAR
Current report	6-K	Apr 17, 2026	Apr 17, 2026	SEC EDGAR
Current report	6-K	Apr 16, 2026	Apr 16, 2026	SEC EDGAR
Current report	6-K	Apr 7, 2026	Apr 7, 2026	SEC EDGAR
Current report	6-K	Mar 30, 2026	Mar 30, 2026	SEC EDGAR
Current report	6-K	Mar 19, 2026	Mar 19, 2026	SEC EDGAR
Current report	6-K	Mar 19, 2026	Mar 19, 2026	SEC EDGAR
Current report	6-K	Mar 17, 2026	Mar 17, 2026	SEC EDGAR
Current report	6-K	Mar 5, 2026	Mar 5, 2026	SEC EDGAR
Annual report	20-F	Dec 31, 2025	Mar 5, 2026	SEC EDGAR
Current report	6-K	Mar 5, 2026	Mar 5, 2026	SEC EDGAR
Current report	6-K	Mar 2, 2026	Mar 2, 2026	SEC EDGAR
Current report	6-K	Feb 27, 2026	Feb 27, 2026	SEC EDGAR
Current report	6-K	Jan 13, 2026	Jan 13, 2026	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Evaxion A/S's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-5 reverse split on Jan 14, 2025
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is EVAX.

Compare: EVAX vs IPHA · EVAX vs MOLN · EVAX vs ELOX · EVAX vs ATRA · EVAX vs TCRX

Revenue growth125.1% · median -67.9%

Operating margin-122.7% · median -1295.2%

Net margin-102.4% · median -1293.9%

Company	Revenue	Growth
EVAX	$7.53M	+125.1%
TCRX	$5.19M	-38.4%
ATRA	$3.97M	-97.4%
IPHA	–	–
MOLN	–	–
ELOX	–	–

Company

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 45
Held by institutions: 0.4%
Auditor: EY Godkendt Revisionspartnerselskab
SEC CIK: 1828253

Advertisement
300 × 250

See a number that looks wrong?